What Is Retatrutide?
A breakthrough triple-hormone obesity treatment developed by Eli Lilly. Retatrutide simultaneously targets three metabolic pathways — making it the most potent weight-loss therapy ever tested in clinical trials.
The Simple Explanation
What Retatrutide is, where it comes from, and why it matters
A GLP-1/GIP/Glucagon Triple Agonist
Retatrutide (also known by its development code LY3437943) is a once-weekly injectable peptide drug developed by Eli Lilly. Unlike earlier weight-loss medications that target a single hormone receptor, Retatrutide activates three at the same time: the GLP-1, GIP, and Glucagon receptors.
This triple-action approach addresses weight from three separate physiological angles simultaneously — suppressing appetite, improving metabolism, and directly accelerating fat breakdown. No approved obesity drug currently does all three.
Developed by Eli Lilly
Eli Lilly, the pharmaceutical giant already behind Tirzepatide (Mounjaro/Zepbound), developed Retatrutide as the next evolution in the GLP class of obesity medicines. Building on Tirzepatide’s dual-agonist success, Lilly added Glucagon receptor agonism — creating a triple agonist that targets energy expenditure in ways the dual-agonist cannot.
Phase 2 trial results, published in the New England Journal of Medicine in 2023, showed an unprecedented average weight reduction of up to 24.2% over 48 weeks — the highest ever recorded in an obesity drug trial at that time.
The Three Hormones Explained
Understanding each target helps explain why Retatrutide works better than anything before it
GLP-1 (Glucagon-Like Peptide-1)
GLP-1 is a gut hormone released after eating. It tells the brain you’re full, slows gastric emptying so food stays in the stomach longer, and stimulates insulin release. This is the same receptor targeted by Semaglutide (Ozempic/Wegovy) and Tirzepatide.
GIP (Glucose-Dependent Insulinotropic Polypeptide)
GIP works alongside GLP-1 to enhance insulin secretion and improve how efficiently your body uses glucose. It also plays a role in fat cell metabolism. Activating both GLP-1 and GIP together produces a synergistic effect stronger than either alone — this is why Tirzepatide outperformed Semaglutide.
Glucagon (The “Fat-Burning” Hormone)
This is the key differentiator. Glucagon is the body’s primary fat-mobilizing hormone. It signals fat cells to break down stored triglycerides and raises energy expenditure. Normally glucagon and GLP-1 oppose each other — but Retatrutide activates both simultaneously in a balanced ratio, harnessing glucagon’s fat-burning power without its blood sugar-raising effects.
The Evolution of Weight Loss Medicine
Retatrutide is the latest — and most powerful — step in a rapidly advancing drug class
Liraglutide (Saxenda)
GLP-1 Single Agonist — Novo Nordisk
The first GLP-1 receptor agonist approved for obesity. Delivered daily, it produced modest ~5-8% weight loss — meaningful, but limited.
Semaglutide (Wegovy / Ozempic)
GLP-1 Single Agonist — Novo Nordisk
A more potent GLP-1 agonist delivering weekly injections. A landmark drug with 10-15% weight loss in trials, it transformed the obesity treatment landscape globally.
Tirzepatide (Mounjaro / Zepbound)
GLP-1 + GIP Dual Agonist — Eli Lilly
Adding GIP receptor activation to GLP-1 created a step-change improvement. Tirzepatide achieved 20-22% weight loss in SURMOUNT trials — significantly outperforming Semaglutide.
Retatrutide (LY3437943)
GLP-1 + GIP + Glucagon Triple Agonist — Eli Lilly
The addition of Glucagon receptor agonism creates a third lever: direct fat burning and increased resting energy expenditure. Phase 2 data showed 24.2% average weight loss — the highest recorded for any obesity drug in clinical history.
Who Is Retatrutide For?
Retatrutide is a prescription treatment — understanding candidacy is the first step
Good Candidates
- Adults with a BMI of 30 or above (obesity)
- Adults with BMI 27+ and at least one weight-related condition (type 2 diabetes, hypertension, sleep apnoea)
- People who have not achieved sufficient weight loss through diet and exercise alone
- Those who have previously used Semaglutide or Tirzepatide with unsatisfactory results
- Adults aged 18–75 without contraindicated medical conditions
Not Currently Suitable
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Pregnancy or planning to become pregnant
- Severe gastrointestinal disease (gastroparesis)
- Type 1 diabetes
Requires Evaluation
- Existing diabetes medications (dose adjustments likely needed)
- Kidney or liver disease (needs assessment)
- Active cardiovascular conditions
- History of eating disorders
- Currently breastfeeding
A free consultation with our medical team will determine your candidacy with no obligation.
The Clinical Evidence
What the trial data actually shows
At the highest dose (12mg) over 48 weeks in Phase 2. This compares to 14.9% for Semaglutide and 20.9% for Tirzepatide in their respective pivotal trials.
The majority of participants in the highest-dose group achieved meaningful, clinically significant weight loss — versus around 37% for Semaglutide.
Across dose groups, liver fat content was dramatically reduced — making Retatrutide a highly promising treatment for Non-Alcoholic Fatty Liver Disease (NAFLD).
Average reduction in waist circumference per 5% body weight lost, indicating visceral fat (the dangerous abdominal fat) was preferentially reduced.
Data sourced from the Phase 2 RETATRUTIDE trial (Eli Lilly, published NEJM 2023) and the ongoing Phase 3 TRIUMPH trials. Results may vary between individuals. All statistics refer to placebo-controlled trial populations under medical supervision.
Common Questions About Retatrutide
Straightforward answers to what people ask most
Is Retatrutide the same as Ozempic or Mounjaro?
+No — they are related but distinct. Ozempic (Semaglutide) targets one hormone receptor (GLP-1). Mounjaro/Zepbound (Tirzepatide) targets two (GLP-1 + GIP). Retatrutide goes further by adding a third: the Glucagon receptor. This additional mechanism is primarily responsible for its superior weight-loss results. Think of it as the next generation beyond both.
Is Retatrutide FDA approved?
+Not yet — Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH program) in the United States. FDA approval is anticipated in 2026 or 2027 pending trial completion. However, it is available through licensed medical providers in Thailand under supervised prescription. This is a legal and medically supervised pathway used regularly for emerging treatments in countries with different regulatory frameworks.
How is Retatrutide different from a diet pill?
+Completely different. Traditional diet pills attempt to suppress appetite through stimulants or block fat absorption mechanically. Retatrutide works at the hormonal level — it mimics and amplifies the body’s own natural signalling systems. It resets the brain’s hunger and satiety set point, improves metabolic function, and increases resting energy expenditure. The results are significantly more powerful and the mechanism is well understood through rigorous clinical research.
Will I have to inject myself forever?
+Not necessarily. Treatment duration is personalised based on your goals and response. Many patients use Retatrutide for 6-12 months to reach their target weight, then transition to a maintenance phase with reduced dosing, or discontinue with a carefully managed tapering protocol. Lifestyle habits developed during treatment help sustain results. Your medical team will plan the right exit strategy for you.
Is the 24% weight loss figure realistic for me?
+The 24% figure is the trial average at the highest dose over 48 weeks, and individual results varied. Some participants lost less; some lost more. Your results will depend on starting weight, dose achieved, lifestyle factors, and metabolic health. However, even outcomes significantly below the trial average represent substantial, meaningful weight loss. During your consultation, we can discuss realistic expectations based on your individual profile.
Ready to Learn If You’re a Candidate?
Our medical team in Thailand provides free consultations to assess your suitability for Retatrutide and answer any clinical questions you have.
- + Thorough health assessment and medical history review
- + Honest discussion of expected results for your profile
- + Full explanation of the dosing protocol
- + No obligation, no pressure
- + Available in English and Thai
Get Free Recommendation and Suggestion
Confirmation within 24 hours · No obligation